Chronic Hepatitis Clinical Trial
Official title:
The Impact of Hepatic Steatosis on Chronic Hepatitis B Virus Infection
Verified date | July 2023 |
Source | Sohag University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study aims to evaluate the prevalence and severity of hepatic steatosis in CHB and investigate the relationship between hepatic steatosis and viral load, liver biochemistry, liver fibrosis, and inflammation in CHB
Status | Completed |
Enrollment | 91 |
Est. completion date | July 15, 2023 |
Est. primary completion date | June 30, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: Hepatitis B surface antigen (HBsAg) carriers presented to the Tropical Medicine and Gastroenterology outpatient clinic, at Sohag University Hospital Exclusion Criteria: Patients with serological evidence of HCV. HBV patients who had received or are currently under anti-viral therapy. Alcohol consumption. Decompensated liver disease. Patients with HCC. Patients are known to have another chronic liver disease (e.g. autoimmune hepatitis, primary biliary cirrhosis, Wilson's disease, Haemochromatosis, or drug-induced chronic hepatitis). Patients with contraindications to liver biopsy such as uncooperative patients, prothrombin time (PT) >4 seconds more than control, INR greater than 1.6, platelets count <100.000/mm3. |
Country | Name | City | State |
---|---|---|---|
Egypt | Faculty of medicine | Sohag |
Lead Sponsor | Collaborator |
---|---|
Sohag University |
Egypt,
European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017 Aug;67(2):370-398. doi: 10.1016/j.jhep.2017.03.021. Epub 2017 Apr 18. — View Citation
Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016 Jul;64(1):73-84. doi: 10.1002/hep.28431. Epub 2016 Feb 22. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | prevalence of hepatic steatosis in CHB | Number of cases with hepatic steotosis in CHB | January 2023 to july 2023 will be included in the study | |
Primary | degree of hepatic steatosis in CHB | Mild, or Moderate or severe degree | January 2023 to july 2023 will be included in the study |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT01833611 -
Entecavir for Chronic Hepatitis B Patients With Persistently Normal ALT
|
Phase 4 | |
Completed |
NCT00771446 -
Safety & Efficacy of the Extracorporeal Liver Assist Device (ELAD) System in Patients With Hepatic Insufficiency
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03731923 -
Abbreviated MRI for HCC Surveillance
|
N/A | |
Recruiting |
NCT03013556 -
Study on an Optimal Antiviral Treatment in HBeAg Positive Chronic Hepatitis B Patients
|
Phase 4 | |
Recruiting |
NCT05181826 -
Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer
|
||
Active, not recruiting |
NCT02143180 -
Accuracy of RTE for Evaluating Hepatic Fibrosis in Chronic Hepatitis: a Prospective Multicenter Study
|
N/A | |
Completed |
NCT00596414 -
Sedation and Analgesia for Transjugular Liver Biopsy: A Randomized Double Blind Placebo Controlled Trial
|
Phase 4 | |
Active, not recruiting |
NCT02772003 -
DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection
|
Phase 1 | |
Terminated |
NCT04775797 -
Safety, Tolerability, and Pharmacokinetics of AB-836 in Healthy Subjects and Subjects With Chronic HBV Infection
|
Phase 1 | |
Terminated |
NCT03487848 -
Evaluation of Daclatasvir (DCV) in Combination With Sofosbuvir (SOF) in Children With Chronic Hepatitis C (CHC) Infection
|
Phase 2 | |
Recruiting |
NCT02822079 -
DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection
|
Phase 1 | |
Recruiting |
NCT04446832 -
VACcination of LIver Transplantation Candidates
|
||
Completed |
NCT01121705 -
Efficacy Study of New Therapeutic Schedules in Naive Hepatitis C Virus (HCV) Patients Infected With Genotype 3 (HCV-3)
|
Phase 3 | |
Completed |
NCT02742597 -
Patient-Centred Innovations for Persons With Multimorbidity - Ontario
|
N/A | |
Not yet recruiting |
NCT05062967 -
Evaluation of Orthohepevirus C Infection as an Emerging Cause of Zoonotic Origin Disease
|
||
Completed |
NCT01380938 -
Different Ribavirin Dosages and Different Duration of Treatment in Combination With PegInterferon in Patients With Genotype 2 and 3 (WRITE)
|
Phase 3 | |
Recruiting |
NCT01413360 -
The Effect of High Dose Vitamin C on the Liver Function in Chronic Hepatitis Patients
|
Phase 4 | |
Terminated |
NCT00496158 -
Efficacy and Safety of Clevudine Compared With Adefovir in Patients With Chronic Hepatitis Due to Hepatitis B Virus
|
Phase 3 | |
Terminated |
NCT00496002 -
Efficacy and Safety of Clevudine Compared With Adefovir in Patients With HBeAg Positive Chronic Hepatitis Due to Hepatitis B Virus
|
Phase 3 | |
Completed |
NCT02789800 -
Patient-Centred Innovations for Persons With Multimorbidity - Quebec
|
N/A |